|
To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture. Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture. conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture. Clinical research trials and To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture. health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture.. To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture. Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture. clinical trial. Participants oftentimes recieve the most expert healthcare available for their To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture. condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture. To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture.
To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture.
For Condition: Hip Fracture,Osteoporosis
Status: Recruiting
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: To evaluate that an investigational drug given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) skeletal fractures. All patients will receive vitamin D and calcium.
Details: Hip fractures are the most devastating of the osteoporotic fractures. Patients with hip fractures lose bone mass and muscle mass in the year following the fracture. There is a very high risk of subsequent fractures after hip fracture in both men and women. These secondary fractures significantly impact the quality of life of patients already struggling to recover from their initial hip fracture. Men and women with hip fractures have much to gain from the development of an effective secondary fracture prevention intervention.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Male or female ages 50 years or older - Must have both legs - Must have a recent hip fracture repair in the past 90 days - Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture Exclusion Criteria: - Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate)
Total Enrollment: 1714
Location and Contact Information:
University of Alabama at Birmingham *Recruiting*
Birmingham, Alabama, 35294-3708
United States
Recruiting Cheryl Ferren 205-934-1444
San Antonio Medical Clinical Research Center *Recruiting*
San Antonio, Texas, 78229
United States
Recruiting Marisa Walsh 210-614-4800
Wayne State University *Recruiting*
Detroit, Michigan, 48201
United States
Recruiting Barbara Lloyd 858-541-3459
Victory Springs Inc *Recruiting*
Reisterstown, Maryland, 21136
United States
Recruiting Jean Downing 410-526-1490
Galesburg Orthopedic Services LTD *Recruiting*
Galesburg, Illinois, 61401
United States
Recruiting Reva Hennenfent 309-342-0194
University of North Carolina at Chapel Hill *Recruiting*
Chapel Hill, North Carolina, 27599
United States
Recruiting Almas Abbas 919-966-9718
Atlanta Resarch Center *Recruiting*
Decatur, Georgia, 30033
United States
Recruiting Emily Kuhnmuench 404-298-9951
Mount Sinai School of Medicine *Recruiting*
New York City, New York, 10029
United States
Recruiting Peter Bevis 212-241-8797
Sargent Rehabilitation Center *Recruiting*
Warwick, Rhode Island, 02818
United States
Recruiting Josephine Dutra 401-886-6621
Duke University Medical Center *Recruiting*
Durham, North Carolina, 27710
United States
Recruiting Amy Wright 919-668-1368
J. Paul Sticht Center on Aging and Rehabilitation *Recruiting*
Winston Salem, North Carolina, 27157
United States
Recruiting Warner Starkey 336-713-8117
Sharp HealthCare *Recruiting*
San Diego, California, 92123
United States
Recruiting Terry Peters 858-541-3459
Health East Osteoporosis Care *Recruiting*
Woodbury, Minnesota, 55125
United States
Recruiting Julie Morancey 651-232-0001
Clinical Research Center of Reading, LLP *Recruiting*
West Reading, Pennsylvania, 19611-1124
United States
Recruiting Sheila Mace 610-375-2466
Center for Orthopaedic Research and Education *Recruiting*
Houston, Texas, 77030
United States
Recruiting Gary Kiebzak 832-355-3224
Brackenridge Hospital *Recruiting*
Austin, Texas, 78701
United States
Recruiting Connie Craig 512-324-1000
Osteoporosis Diagnostic Center *Recruiting*
Eureka, California, 95503
United States
Recruiting Barbara Marchi 707-445-1600
Lattimore Orthopaedics, P.C. *Recruiting*
Rochester, New York, 14620
United States
Recruiting Michel Neracker 585-473-1033
Ohio State University *Recruiting*
Columbus, Ohio, 43210
United States
Recruiting John Landoll 614-293-3838
Danville Regional Medical Center *Recruiting*
Danville, Virginia, 24541
United States
Recruiting April Hardy 434-799-3753
Mercy Arthritis and Osteoporosis Center *Recruiting*
Des Moines, Iowa, 50322
United States
Recruiting Joyce Brown 515-643-9699
Maine Medical Center Research Institute *Recruiting*
Portland, Maine, 04074
United States
Recruiting Helen Cyr-Alves 207-885-8106
University of Wisconsin Hospital and Clinics *Recruiting*
Madison, Wisconsin, 53705
United States
Recruiting Diane Krueger 608-265-6410
United Osteoporosis Center Health Services *Recruiting*
Gainesville, Georgia, 30501
United States
Recruiting Katie Parrish 770-534-5154
Nine Medical Park *Recruiting*
Columbia, South Carolina, 29203
United States
Recruiting Linda Sherriff 803-434-4439
DataPharm, Inc. *Recruiting*
Canfield, Ohio, 44406
United States
Recruiting Sandra Treleven 330-533-3646
Additional Information:
Study ID Numbers: CZOL446H2310;
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046254
Other Hip Fracture Studies:
1. Patient- and Physician-Based Osteoporosis Education
2. Bone Estrogen Strength Training
3. Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
4. Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency
5. To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture.
Related Studies:
Other Hip Fracture Clinical Trials
Other Georgia Clinical Trials
Other Decatur Clinical Trials
To evaluate the ability of an investigational drug to reduce the rate of all subsequent skeletal fractures after a hip fracture.
|
|
|
|
|
|
|
|